Latest News
Episurf Medical awarded new European patent and Malaysian market approval
17 January 2022 - Episurf Medical AB (STO:EPIS-B), a Swedish provider of minimally invasive and individualised treatment alternatives for people with painful joint injuries, said on Monday that it has received notice from the European Patent Office t...
Pfizer to invest in production plant in south-west France for its COVID-19 anti-viral pill
17 January 2022 - US pharmaceutical company Pfizer Inc (NYSE:PFE) is to add a production facility in France for paxlovid, its antiviral COVID-19 pill, as part of a plan to invest EUR520m in the country over the next five years, Reuters news agency re...
Northern Ireland study suggests COVID-19 causes birth-related complications in pregnant women
17 January 2022 - A new study by the University of Edinburgh in Northern Ireland has found an increased risk of birth-related complications after getting COVID-19 in pregnant woman, BBC News reported on Monday.The study has found pre-term births, sti...
England to offer booster jab for 16 and 17 years old
17 January 2022 - A COVID-19 booster jab for 16 and 17-year-olds in England can now be booked or they can attend a walk-in vaccination centre, BBC News reported on Monday.Invitations will initially be sent to the 40,000 teens who had a second vaccine...
AbbVie's Atopic Dermatitis drug RINVOQ (upadacitinib) receives US FDA approval
17 January 2022 - AbbVie (NYSE: ABBV), a United States-based biopharmaceutical company, announced on Friday that it has received approval from the United States Food and Drug Administration (FDA) for its RINVOQ (upadacitinib) to treat moderate to sev...